RT Journal Article
SR Electronic
T1 Frequent Quantitation of Circulating Tumor Cells Predictive of Real-Time Therapy Response
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.03.22268688
DO 10.1101/2022.01.03.22268688
A1 Lim, Christine M.
A1 Shi, Junli
A1 Vo, Jess
A1 Phyo, Wai Min
A1 Hu, Min
A1 Tan, Min Chin
A1 Tee, Augustine
A1 Yap, Yoon Sim
A1 Nei, Wenlong
A1 Chan, Daniel
A1 Wong, Seng Weng
A1 Neo, Meusia
A1 Binte Mohammad Mazian, Norhidayah
A1 Ying, Jackie Y.
A1 Tan, Min-Han
A1 Liang, Kaicheng
A1 Mong, Jamie
YR 2022
UL http://medrxiv.org/content/early/2022/01/04/2022.01.03.22268688.abstract
AB Precision medicine is playing an increasingly important role in cancer management and treatment. Specifically in the field of oncology, circulating tumor cells (CTCs) hold significant promise in enabling non-invasive prognostication and near real-time monitoring to individualize treatments. In this study, we present strong associations between CTC subtype counts with treatment response and tumor staging in lung, nasopharyngeal and breast cancers. Longitudinal analysis of CTC count changes over short-time windows further reveals the ability to predict treatment response close to real-time. Our findings demonstrate the suitability of CTCs as a definitive blood-based metric for continuous treatment monitoring. Robust processing of high-throughput image data, explainable classification of CTC subtypes and accurate quantification were achieved using an in-house image analysis system ‘CTC-Quant’, which showed excellent agreement with expert opinion upon extensive validation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by the Agency for Science, Technology and Research Biomedical Research Council Strategic Positioning Fund (SPF2012/003) to Min-Han Tan (MT) and Jackie Y. Ying (JYY). W.L.N is supported by the National Medical Research Council Fellowship (NMRC/ MOH-000166-00).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the SingHealth Centralised Institutional Review Board for Changi General Hospital and National Cancer Centre and the NHG Domain Specific Review Board for National University Hospital.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or supplementary material.